Just three months after the GAVI Alliance secured $4.3 billion in promised support from donors at its first pledging conference, the Geneva-based organization has considerably expanded its campaign against some of leading killers of children worldwide. Today, GAVI announced funding for 37 developing nations, mostly in sub-Saharan Africa, to receive discounted vaccines targeted against rotavirus, pneumococcal disease and other deadly infections.
“This is really a sign that GAVI is back in business big time,” Orin Levine, executive director of the Johns Hopkins Bloomberg School of Public Health’s International Vaccine Access Center in Baltimore, told Nature Medicine. “There’s a big demand to use these vaccines in developing countries if we can just make the funding available.”
For more on the roll-out of the rotavirus vaccine — which protects against severe diarrhea, a major killer of children under five — check out the news story from this week’s Nature.